Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease
Pulmonary hypertension (PH) with developmental lung disease is a life-threatening disease and accounts for 10%-12% of pediatric PH patients. Administration of specific pulmonary vasodilators to pediatric PH patients has brought about improvement of their long-term prognosis. Intravenous epoprostenol...
Saved in:
Main Authors: | Yoshie Fukasawa (Author), Hidenori Yamamoto (Author), Miharu Ito (Author), Akiko Saito (Author), Kiyotaka Go (Author), Yoshihito Morimoto (Author), Kazushi Yasuda (Author), Yoshiaki Sato (Author), Masahiro Hayakawa (Author), Taichi Kato (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
by: Julia Timofeev, et al.
Published: (2013) -
Microbial challenge test of a novel epoprostenol sodium formulation
by: Bandilla D, et al.
Published: (2017) -
Neural regulation of respiration during exercise -Beyond the conventional central command and afferent feedback mechanisms-
by: Koji Ishida, et al.
Published: (2012) -
Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
by: Lambert O, et al.
Published: (2012) -
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
by: Lambert O, et al.
Published: (2012)